Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020
Pacira BioSciences, Inc. (NASDAQ: PCRX) will report its second quarter financial results on August 6, 2020, before market opening. Following the announcement, a live conference call will take place at 8:30 a.m. ET. Participants can join via a dedicated dial-in number or through a webcast available on the company’s investor page. A replay of the call will be accessible for one week post-event. Pacira specializes in non-opioid pain management and regenerative health solutions, prominently featuring its long-acting analgesic, EXPAREL®, launched in April 2012.
- The company is set to report its second quarter financial results, indicating ongoing business operations.
- Pacira continues to advance its mission in non-opioid pain management with products like EXPAREL®.
- None.
PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
To participate in the conference call, dial 1-877-845-0779 and provide the passcode 3276818. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.
For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 3276818. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
When will Pacira BioSciences report its second quarter financial results?
What time is the Pacira BioSciences conference call on August 6, 2020?
How can I access the conference call for Pacira BioSciences?